All News

Pravastatin sodium (Pravachol) is indicated as an adjunctive therapy to diet to lower the risk of myocardial infarction, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident congenital heart disease.

Legatrin PM is intended for relief of lower body pain.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss the underlying causes of the hematology-oncology pharmacist great migration from the field.

Surprising turn of events is a strong message to the pharmaceutical industry about the acceptable developmental pathway for this drug class.

Andre Harvin, PharmD, MS, executive director of Pharmacy, Oncology Services at Cone Health, discusses methods of accomplishing greater workforce diversity in the field of oncology pharmacy.

Pharmacy Times spoke with Paul Feuerstadt, MD, FACG, AGAF, about the investigative C. difficile treatment RBX2660.

In a sector that relies heavily on opacity, who knows what might be found in the government's inquiry?

Rates of influenza and associated hospitalizations demand late-season vigilance.

If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.

New data show that after 4 years of treatment, 78.8% of patients who continuously received ofatumumab achieved no evidence of disease activity-3 (NEDA-3) compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Bhavesh Shah, RPh, BCOP, steering committee co-chair of the 2022 ATOPP Summit, discusses the impact of the annual ATOPP summit on the oncology pharmacy field.

The Pharmacy Times® Future of Pharmacy Resource Center is a comprehensive source on the evolution of the pharmacy profession and the growing roles of pharmacists

The Future of Pharmacy initiative is telling the story of where the profession has been and where it is headed.

Sonidegib is a biphenyl carboxamide that blocks the signaling in the hedgehog pathway.

The first step to reducing recurrent C. difficile infections is prevention.

Paul Feuerstadt, MD, FACG, AGAF, discussed the investigative C. difficile treatment RBX2660 and how it impacts time to recurrence.

Nearly 63% of newly diagnosed patients have advanced colorectal cancer, which requires more aggressive treatment and reduces the associated 5-year survival rate.

Ashwagandha KSM-66 (Anxiety & Stress Relief) from Nature’s Bounty is indicated to help manage occasional stress and anxiety.

Many patients with heart failure are hesitant to receive the COVID-19 vaccine due to the fear of myocarditis.

Findings from a study highlight the efficacy and safety of bulevirtide for the treatment of chronic hepatitis delta virus.

Livalo is an HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet in adults with primary hyperlipidemia or mixed dyslipidemia.

Andre Harvin, PharmD, MS, executive director of Pharmacy, Oncology Services at Cone Health, discusses the importance of putting precision medicine programs into oncology practices with pharmacists leading the way.

Pharmacy Times will be covering the 2022 ATOPP Summit live in San Diego, CA.

Amy Woodard, PharmD, BCOP, the steering committee co-chair of the 2022 ATOPP Summit, highlights key topics and discussions at the in-person summit in July in San Diego, CA.

Pharmacy Times will be covering McKesson ideaShare 2022 live in Washington, DC, from July 7 through 10.

This month's product news features acyclovir oral suspension, vigabatrin oral solution, and budesonide and formoterol bumarate dihydrate inhalation aerosol.

As we learn more about inflammatory syndromes, we may get better at using laboratory tests to identify and isolate the actual cellular and chemical processes that drive them.

Paul Feuerstadt, MD, FACG, AGAF, discussed research into the novel C. difficile treatment RBX2660 and what investigators have found about its efficacy in key subgroup analyses.

How would you respond to these patients questions?

Metformin has been shown to decrease pro-inflammatory cytokines that appear to improve the immune response to tumor cells and improve the efficacy of immunotherapy.